{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T16:17:04Z","timestamp":1710346624572},"reference-count":4,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,13]]},"DOI":"10.7759\/cureus.54143","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T01:10:36Z","timestamp":1707873036000},"source":"Crossref","is-referenced-by-count":0,"title":["Programmed Death-1 Inhibitor Immunotherapy-Induced Symptomatic Toxic Thyroid Nodule"],"prefix":"10.7759","author":[{"given":"Owen","family":"Cole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prahasith","family":"Kamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Warman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari SM","year":"2018","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018, 19:325-33. 10.1007\/s11154-018-9463-2","journal-title":"Rev Endocr Metab Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol M","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, et al.. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017, 58:70-6. 10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250696","article-title":"Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer","volume":"15","author":"Kataoka S","year":"2022","unstructured":"Kataoka S, Matsuno K, Sugano K, Takahashi K. Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer. BMJ Case Rep. 2022, 15:250696. 10.1136\/bcr-2022-250696","journal-title":"BMJ Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona Z","year":"2023","unstructured":"Cardona Z, Sosman JA, Chandra S, Huang W. Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol (Lausanne). 2023, 14:1157805. 10.3389\/fendo.2023.1157805","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/229480-programmed-death-1-inhibitor-immunotherapy-induced-symptomatic-toxic-thyroid-nodule","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T01:10:38Z","timestamp":1707873038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/229480-programmed-death-1-inhibitor-immunotherapy-induced-symptomatic-toxic-thyroid-nodule"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":4,"URL":"https:\/\/doi.org\/10.7759\/cureus.54143","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,13]]}}}